(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

10/509732

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number
WO 03/082288 A1

(51) International Patent Classification[7]: A61K 31/495, 31/496, C07D 295/18, 295/22, 317/58, 239/42, 209/20, 333/60

(21) International Application Number: PCT/GB03/01463

(22) International Filing Date: 3 April 2003 (03.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/369,337 3 April 2002 (03.04.2002) US

(71) Applicant *(for all designated States except US)*: **PROLIFIX LIMITED** [GB/GB]; 87A Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **WATKINS, Clare, J.** [GB/GB]; 10b Milton Road, Sutton Courtenay, Abingdon, Oxfordshire OX14 4BS (GB). **ROMERO-MARTIN, Maria-Rosario** [ES/GB]; 11 Crookdale Beck, Didcot, Oxfordshire OX11 7US (GB). **RITCHIE, James** [GB/GB]; Prolifix Limited, 87A Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **FINN, Paul, W.** [GB/GB]; Prolifix Limited, 87A Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **KALVINSH, Ivars** [LV/LV]; Latvian Institute of Organic Synthesis, Dept. of Medicinal Chemistry, Aizkraukles iela 21, LV-1006 Riga (LV). **LOZA, Einars** [LV/LV]; Latvian Institute of Organic Synthesis, Dept. of Medicinal Chemistry, Aizkraukles iela 21, LV-1006 Riga (LV). **DIKOVSKA, Klara** [LV/LV]; Latvian Institute of Organic Synthesis, Dept. of Medicinal Chemistry, Aizkraukles iela 21, LV-1006 Riga (LV). **STARCHENKOV, Igor** [LV/LV]; Latvian Institute of Organic Synthesis, Dept. of Medicinal Chemistry, Aizkraukles iela 21, LV-1006 Riga (LV). **LOLYA, Daina** [LV/LV]; Latvian Institute of Organic Synthesis, Dept. of Medicinal Chemistry, Aizkraukles iela 21, LV-1006 Riga (LV). **GAILITE, Vjia** [LV/LV]; Latvian Institute of Organic Synthesis, Dept. of Medicinal Chemistry, Aizkraukles iela 21, LV-1006 Riga (LV).

(74) Agents: **BRASNETT, Adrian, H.** et al.; Mewburn Ellis, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv)) for US only*

Published:
— *with international search report*

[Continued on next page]

(54) Title: CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS



(1)

(57) Abstract: This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula:[Insert formula]wherein: Cy is independently a cyclyl group; Q^1 is independently a covalent bond or cyclyl leader group; the piperazin-1,4-diyl group is optionally substituted; J^1 is independently a covalent bond or -C(=O)- ; J^2 is independently -C(=O)- or -$S(=O)_2$- ; Q^2 is independently an acid leader group; wherein: Cy is independently: C_{3-20}carbocyclyl, C_{3-20}heterocyclyl, or C_{5-20}aryl; and is optionally substituted; Q^1 is independently: a covalent bond; C_{1-7}alkylene; or C_{1-7}alkylene-X-C_{1-7}alkylene, -X-C^{1-7}alkylene, or C_{1-7}alkylene-X-, wherein X is -O- or -S-; and is optionally substituted; Q^2 is independently: C_{4-8}alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or: Q^2 is independently: C_{5-20}arylene; C_{5-20}arylene-C_{1-7}alkylene; C_{1-7}alkylene-C_{5-20}arylene; or, C_{1-7}alkylene-C_{5-20}arylene-C_{1-7}alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both *in vitro and in vivo*, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

WO 03/082288 A1